HUM Stock Analysis
💡 Quick Answer
Across 4 APEX technical signals, HUM is currently split between bullish and bearish readings — 0 bullish, 0 bearish as of 2026-06-11. Run a live analysis to see the current composite score.
HUM is the highest-beta large-cap managed care stock with ATR of 4-6% due to its pure-play Medicare Advantage concentration. Post-earnings moves of 8-14% are among the largest in healthcare.
Humana is the second-largest Medicare Advantage (MA) insurer in the U.S., with approximately 5 million MA members. Unlike UnitedHealth or Cigna, Humana's business is almost entirely concentrated in Medicare Advantage. The privatized Medicare program that pays private insurers a risk-adjusted premium to cover Medicare beneficiaries. This concentration creates extremely high exposure to CMS (Centers for Medicare & Medicaid Services) annual rate decisions, which are announced each April and determine Humana's reimbursement rates for the following plan year.
Why Do Traders Watch HUM?
HUM is the highest-beta large-cap managed care stock with ATR of 4-6% due to its pure-play Medicare Advantage concentration. Post-earnings moves of 8-14% are among the largest in healthcare. Medical cost trends and MLR data are the primary drivers. CMS rate announcements in April each year are the most impactful single annual event for HUM. When medical utilization spikes (post-COVID pent-up demand, behavioral health) or CMS underfunds MA rates, HUM can lose 20-30% in a single quarter.
Is HUM a Buy Right Now? Current Signal Readings
The Centers for Medicare & Medicaid Services announces Medicare Advantage benchmark rates each April for the following plan year. And this is Humana's single most important annual event. Rate increases above 3% are bullish; below 1% create MA profitability pressure. The preliminary rate notice (February) provides a 60-day preview of the final decision, giving traders advance positioning opportunity.
Humana's Medical Loss Ratio. Medical costs as a percentage of premium revenue. Directly determines profitability. MLR above 91% signals the company is paying out more in medical costs than its rate increases allow. Post-COVID utilization normalization (more procedures, more specialist visits) has been the primary MLR pressure driver. Each quarter of MLR stabilization below 89% is a positive signal.
HUM's RSI can reach extreme levels driven by medical cost announcements. RSI below 32 following MLR guidance cuts. When the MA market structure remains intact. Have historically been contrarian entries for traders willing to hold through the earnings normalization cycle. These RSI extremes typically resolve over 2-3 quarters as pricing actions catch up to medical trend.
Medicare Advantage enrollment is growing 5-7% annually as more Baby Boomers turn 65 and choose MA over traditional Medicare. Humana's net member additions each open enrollment period (November-January) signal whether it is holding or gaining market share against UNH and CVS Health. Member growth above 300,000/year confirms the MA platform is healthy despite near-term profitability pressure.
📋 HUM Key Stats for Traders
APEX combines RSI, MACD, Fibonacci, Volume, and 4 more signals into one composite score in under 30 seconds.
Analyze HUM Free →